ℹ️ Observational Association Only Evidence
Researchers analyzed administrative claims for 2,031 patients aged 10 to 17 years who initiated GLP-1 receptor agonist therapy without a recently recorded nutritional deficiency. Within 12 months, 16.8% received at least one nutritional-deficiency or related-complication diagnosis. Only 23.3% had nutrition therapy or counseling within 180 days. The study describes real-world diagnosis and utilization patterns but cannot determine whether treatment caused deficiencies or whether counseling changed outcomes.
Clinical Considerations
- Vitamin D deficiency dominated the observed signal, rising from 7.6% at six months to 12.4% at one year.
- Nutritional anemia affected 1.5%, iron-deficiency anemia affected 1.4%, and dehydration affected 2.6% within one year.
- Only 5.8% received nutrition care within 30 days; mean time to the first documented encounter was 149 days.
- Higher deficiency rates among patients receiving counseling likely reflect reactive referral or greater detection, not harm from nutrition care.
- Claims codes cannot capture dietary intake, laboratory-confirmed deficiencies, growth trajectories, lean mass changes, or unbilled counseling.
- The 2017–2022 cohort predominantly received liraglutide, limiting generalizability to current semaglutide and tirzepatide prescribing patterns.
Practice Applications
- Consider nutritional history and baseline risk assessment when adolescents begin GLP-1 receptor agonist treatment.
- Monitor growth, dietary adequacy, gastrointestinal intolerance, hydration, and clinically indicated micronutrient markers during follow-up.
- Discuss adequate protein, iron, calcium, and vitamin D intake without interpreting claims-based associations as supplementation guidance.
- Integrate timely dietitian involvement when access permits, while recognizing that prospective evidence has not defined optimal referral timing.
PATIENT EDUCATION
OBESITY/WEIGHT MANAGEMENT
EXERCISE/TRAINING
LEGAL MATTERS
GUIDELINES/RECOMMENDATIONS